Immunoassay reagents for target analytes in stool specimens
By adding casein and animal hemoglobin antibodies to the immunoassay reagent, the false positive detection problem caused by casein interference in feces was solved, which significantly improved the accuracy of stool occult blood detection, and proved that casein is non-specific in feces samples. Adsorption phenomenon and the interference problem is effectively solved by adding blocking components.
Patent Information
- Application Number
- CN202211592993.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2042-12-13
AI Technical Summary
The casein residue in fecal samples has a significant interference to the detection of stool occult blood in immune method, resulting in false positive detection results. In the prior art, casein as a solid-phase carrier blocking agent is believed to not cause interference, and its physicochemical in fecal samples Changes in nature make interference difficult to predict.
Add casein blocking ingredients, such as antibodies and antiserum against casein, as well as animal hemoglobin antibodies to eliminate casein interference in feces samples, through dilution, treatment solution, immune turbidimetric R1 reagent and The addition of R2 reagent reduces false positive test results.
It significantly reduces false positive test results, and basically does not affect the intensity of the detection signal, improves the accuracy of the detection, proves the non-specific adsorption of casein in fecal samples, and effectively solves the interference problem by adding blocking components.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of immunoassay, in particular to an interference blocking component for fecal sample immunoassay of fecal occult blood. Background Art
[0002] Fecal occult blood is also often called fecal occult blood, or FOB (Fecal Occult Blood) in English. It refers to a small amount of bleeding in the digestive tract. Red blood cells are digested and destroyed and mixed into the feces and discharged, but there is no abnormal change in the appearance of the feces. Bleeding cannot be confirmed by the naked eye or under a microscope. Fecal occult blood is usually caused by chronic bleeding (usually intermittent bleeding) in the upper or lower digestive tract. The fecal occult blood test is mainly performed to detect or prevent colon cancer and early digestive tract lesions. Chronic bleeding does not change the color of the stool or produce visible blood. Therefore, fecal occult blood can only be detected clinically through laboratory testing of fecal hemoglobin.
[0003] There are currently two main types of fecal occult blood testing methods, one is the chemical method and the other is the immunological method. The chemical fecal occult blood test uses a solution containing chemical guaiac and oxidizing substances. When the solution meets the hemoglobin in the stool sample, it will turn into a distinct blue color. This blue color is produced by the interaction between the heme part of the red hemoglobin molecule and guaiac. The immunological fecal occult blood test uses hemoglobin antibodies to specifically identify hemoglobin in stool samples for detection. Compared with the chemical method, the immunological method for detecting fecal occult blood has a higher sensitivity and is more likely to detect cancer and precancerous polyps. At the same time, it has a stronger specificity than the chemical method. Therefore, the immunological fecal occult blood test is currently mostly used in clinical practice.
[0004] However, stool samples have complex components and are often interfered with when used in immunoassays to measure hemoglobin, requiring improvements to the reagent system. Summary of the invention
[0005] Casein is a commonly used immunoassay solid phase carrier blocking agent, similar to BSA, used to block the hydrophobic surface of solid phase carriers such as Elisa plates, magnetic beads, and latex to prevent non-specific adsorption on the surface of the solid phase carrier. As a mature, reliable, and widely used solid phase carrier blocking agent, casein itself is rarely reported to interfere with the components of the immunoassay system, and there are no reports of casein causing immunoassay interference in fecal sample analyte detection projects. There are only records of casein interference in milk sample analyte detection studies. The study of Zenker Hannah E.et.al.Foods 2021,10(8),1836 showed that casein in heated milk samples can induce binding with sRAGE and CD36, interfering with the results of ELISA cell assays based on the formation of AGE-receptor ligand complexes; however, the study also emphasized that this interference depends on the cell type, test parameters, and cell surface receptors, and that the interference of casein is greatly reduced after intestinal digestion. US10048262B2 discloses that casein can interfere with the determination of staphylococci in milk in the detection of milk sample analytes.
[0006] Unlike casein in milk samples, which accounts for 80% of the total protein content and maintains a complete protein conformation, it is understandable that such a high content of casein in milk will interfere with the immunoassay of other components in the milk sample. It can be seen that the reports of casein interference with immunoassay in the prior art are concentrated in milk samples and are limited to the detection interference of several limited analytes; however, the residual casein in feces undergoes intestinal digestion, and its physical and chemical properties (mainly micellar state) undergo tremendous changes, and its tendency to induce nonspecific binding and binding strength will also undergo unpredictable changes.
[0007] When developing a latex-enhanced immunoturbidimetric reagent for fecal occult blood, the inventors were surprised to find that residual casein in the feces would produce significant nonspecific adsorption with the latex reagent coupled with human hemoglobin antibodies, causing false positive test results for the samples. This is completely contrary to the cognition of those skilled in the art. Casein, as a typical inert protein, is often used to stabilize latex-enhanced immunoturbidimetric reagents to prevent nonspecific adsorption, and it has not been heard that it itself will cause significant interference in latex-enhanced immunoturbidimetric assays. Although it is unclear whether this is because casein has a nonspecific binding reaction with the components of the detection system based on the physicochemical mechanism, this discovery provides guidance for eliminating false positive test results for fecal occult blood clinical samples. The inventors then added casein blocking components to the detection reagent, effectively eliminating the erroneous test results of false positive samples.
[0008] A first aspect of the present invention provides an immunoassay reagent for a target analyte in a stool sample, which can greatly eliminate the influence of specific interferents in the stool sample.
[0009] The immunoassay reagent comprises a casein blocking component, and the casein blocking component of the present invention is selected from antibodies and antiserum against casein.
[0010] Preferably, the immunoassay reagent is at least one of a sample diluent, a sample processing solution, a sample diluent, an immunoturbidimetric R1 reagent, and an immunoturbidimetric R2 reagent.
[0011] Preferably, the target analyte is human hemoglobin.
[0012] Preferably, the immunoassay is an immunoturbidimetric assay.
[0013] Preferably, the immunoassay is a latex enhanced immunoturbidimetric assay.
[0014] Furthermore, the immunoassay reagent also includes animal hemoglobin antibodies, which are selected from antibodies and antiserum against casein, etc. The animal hemoglobin is selected from pigs, cattle, sheep, chickens, ducks, fish, etc.
[0015] Animal hemoglobin is highly similar to human hemoglobin in structure and can easily cause false positive test results. Similarly, false positive test results in some clinical samples can be eliminated by adding animal hemoglobin antibodies.
[0016] Preferably, the target analyte in the stool sample is human hemoglobin.
[0017] The first aspect of the present invention also provides a kit comprising the aforementioned immunoassay reagent.
[0018] The kit is selected from an immunoturbidimetric detection kit (preferably a latex-enhanced immunoturbidimetric detection kit), a colloidal gold immunoturbidimetric detection kit, a fluorescent immunoturbidimetric detection kit, a chemiluminescent immunoturbidimetric detection kit, and the like.
[0019] A second aspect of the present invention provides a method for eliminating the influence of interfering substances in a stool sample, comprising removing casein from the stool sample.
[0020] The method of removing casein from the stool sample may be to add casein antibodies to the sample; or to pretreat the stool sample by adding caseinase or the like to degrade casein; or to perform other operations to separate and remove casein from the stool sample.
[0021] Optionally, the stool sample can be further depleted of animal hemoglobin.
[0022] Technical effect: The immunoassay reagent containing casein blocking components of the present invention can significantly eliminate the erroneous detection results of false positive clinical stool samples that are easily judged as positive by other detection methods, and basically does not affect the detection signal intensity of clinical stool samples. DETAILED DESCRIPTION
[0023] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature described or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0024] The following embodiments are all implemented on an immunoturbidimetric platform, but this does not mean that the scope of the present invention is limited to the application on an immunoturbidimetric platform.
[0025] Herein, the term "immunoturbidimetric platform" refers to a dynamic determination method for antigen-antibody binding. Its basic principle is: when the antigen and antibody react specifically in a special dilution system and the ratio is appropriate (generally, the antibody is excessive), the soluble immune complex formed is precipitated from the liquid phase under the action of the polymerization promoter (polyethylene glycol, etc.) in the dilution system, forming particles, causing turbidity in the reaction solution. When the antibody concentration is fixed, the amount of the immune complex formed increases with the increase of the amount of antigen in the test sample, and the turbidity of the reaction solution also increases accordingly. By measuring the turbidity of the reaction solution and comparing it with a series of standard products, the content of the antigen in the test sample can be calculated. The latex-enhanced immune turbidimetry is to coat the antibody corresponding to the substance to be tested on the latex particles, so that the volume of the antigen-antibody conjugate is increased. After the light passes through, the intensity changes of the transmitted light and the scattered light are more significant, thereby improving the sensitivity of the test.
[0026] As used herein, the term "reagent" may be understood as a substance or product, etc., regardless of its form or state, and may be either liquid or solid.
[0027] In this article, immunoturbidimetric R1 reagent refers to a buffer reagent used to dilute and dissolve samples, which can remove the interference of interfering substances in the samples; immunoturbidimetric R2 reagent is a reagent containing immunoreactive substances (antibodies or antigens) used to react with the target analyte in the sample to produce a detectable signal (absorbance change).
[0028] Example 1 Human hemoglobin polyclonal antibody coupled to latex microspheres
[0029] 1) Add 100 μL of latex microspheres (PS1016A) to 400 μL of cross-linking solution (50 mM HEPES, pH 6.1) and shake on a shaker to obtain a latex microsphere solution;
[0030] 2) Add 15 μL of EDAC solution to the latex microsphere solution and activate it at 37°C with shaking for 1 hour;
[0031] 3) Add 60 μL of human hemoglobin polyclonal antibody (3 mg / mL, which can be a mixture of three human hemoglobin monoclonal antibodies FOB-REAB-G1-008, FOB-REAB-G1-009, and FOB-REAB-G1-010 purchased from Feipeng Bio; or Dako A0118 human hemoglobin polyclonal antibody purchased from Dako) to the latex microsphere solution and shake cross-link at 37°C for 4 hours;
[0032] 4) Add 60 μL of TW-20 solution and shake at 37°C for 1 hour;
[0033] 5) Add the cross-linking liquid to the centrifuge tube. After centrifugation, carefully discard the supernatant with a pipette;
[0034] 6) Add 2.5 mL of cleaning solution (50 mM glycine + 0.1% NaN3, pH 8.0), vortex, centrifuge again, and carefully discard the supernatant;
[0035] 7) Add 6 mL of latex microsphere suspension (50 mM glycine + 0.1% BSA + 8% sucrose + 0.1% NaN3, pH 8.0) and perform ultrasonic dispersion treatment to obtain R2 reagent.
[0036] Example 2 Preparation of other detection reagents
[0037] Casein antiserum: Casein (Sigma C8654) was used as an immunogen to immunize rabbits and obtain antiserum.
[0038] Casein antibody: The casein antiserum was purified by chromatography to obtain total IgG as casein polyclonal antibody.
[0039] Porcine hemoglobin antiserum: Porcine hemoglobin (Sigma H4131) was used as an immunogen to immunize rabbits and obtain antiserum.
[0040] Porcine hemoglobin antibody: The porcine hemoglobin antiserum was purified by chromatography to obtain total IgG as the porcine hemoglobin polyclonal antibody.
[0041] Bovine hemoglobin antiserum: Bovine hemoglobin (Sigma H2500) was used as an immunogen to immunize rabbits and obtain antiserum.
[0042] Bovine hemoglobin antibody: The bovine hemoglobin antiserum was purified by chromatography to obtain total IgG as bovine hemoglobin polyclonal antibody.
[0043] R1 reagent: 25mmol Tris + 600mM NaCl + 2% PEG6000 + 0.1Tween20
[0044] Standard reagents: Human hemoglobin (Sigma H7379), porcine hemoglobin (Sigma H4131), bovine hemoglobin (Sigma H2500), and casein (Sigma C8654) were added to FOB sample diluent (composed of 25 mM Hepes + 500 mM NaCl + 10 mM Arg + 10 mM Glu + 0.1% EDTA·Na2 + 10% sucrose + 5% trehalose + 0.1% Tween20 + 0.05% Proclin300, pH adjusted to 7.0 with NaOH / HCl) and diluted to gradient concentrations of 0 ng / mL, 31.25 ng / mL, 62.5 ng / mL, 125 ng / mL, 250 ng / mL, 500 ng / mL, and 1000 ng / mL.
[0045] Example 3 On-machine testing process
[0046] Instrument: Fully automatic biochemical analyzer
[0047] Detection process: Pipette 135μL of R1 into the cuvette, incubate at 37℃ for 2 minutes, then pipette 35μL of the sample on the sample plate into the cuvette, stir mechanically, and incubate at 37℃ for 7 minutes; then add 35μL of R2 into the cuvette, stir mechanically, and incubate at 37℃ for 12 minutes. The instrument records the absorbance value at a wavelength of 570nm at 7 minutes and 12 minutes from the time the sample is added to the cuvette. The difference between the absorbance at 12 minutes and 7 minutes is the instrument reading, so sometimes the instrument reading is negative.
[0048] Test Example 1: Test on the effect of casein blocking component itself on human hemoglobin determination, casein on human hemoglobin
[0049] Interference test of the assay reagent and the blocking effect test of the casein blocking component (the reagent used is the human hemoglobin anti-5 from Feipeng Biotechnology)
[0050] In order to test whether casein antibodies themselves would interfere with the determination of human hemoglobin, 1-4% casein blocking components (specifically casein antiserum) were added to the R1 reagent to test gradient concentrations of human hemoglobin standards. The results are shown in Table 1.
[0051] Table 1
[0052]
[0053] To test the interference of casein in the sample on the human hemoglobin determination reagent and the blocking effect of adding casein blocking components,
[0054] 1-4% casein blocking components (specifically casein antiserum) were added to the R1 reagent to test casein standards with gradient concentrations. The results are shown in Table 2.
[0055] Table 2
[0056]
[0057] The results in Tables 1 and 2 show that casein can cause significant signal reactions in human hemoglobin assay reagents, and the addition of casein blocking components can reduce the interference caused by casein. After adding casein blocking components, the activity of the reagent is not affected, and the interference caused by casein can be reduced to a certain extent. The effect is dose-dependent with the concentration of casein antiserum added. However, when the proportion of casein blocking components added is above 2%, the blocking effect increases more slowly as the concentration is further increased, and the background activity of the reagent tends to increase.
[0058] Test Example 2: Test on the influence of animal hemoglobin blocking components on human hemoglobin determination, test on the interference of animal hemoglobin on human hemoglobin determination reagent, and test on the blocking effect of animal hemoglobin blocking components (reagent using Feipeng Bio human hemoglobin antibody)
[0059] In order to test whether the animal hemoglobin blocking component itself would interfere with the determination of human hemoglobin, 1-4% animal hemoglobin antiserum (porcine hemoglobin antiserum: bovine hemoglobin antiserum = 1:1) was added to the R1 reagent as a blocking component to test gradient concentrations of human hemoglobin standards. The results are shown in Table 3.
[0060] Table 3
[0061]
[0062] In order to test the interference of animal hemoglobin in the sample on the human hemoglobin determination reagent and the blocking effect of adding animal hemoglobin blocking components, 1-4% animal hemoglobin antiserum (porcine hemoglobin antiserum: bovine hemoglobin antiserum = 1:1) was added to the R1 reagent as a blocking component to test the gradient concentration of animal hemoglobin standards. The results are shown in Table 4.
[0063] Table 4
[0064]
[0065]
[0066] The above results show that animal hemoglobin will cause a certain degree of signal reaction in the human hemoglobin assay reagent, and the addition of animal hemoglobin blocking components can alleviate the interference caused by animal hemoglobin to a certain extent.
[0067] Test Example 3: Test on the effect of the mixture of casein blocking component and animal hemoglobin blocking component on human hemoglobin determination, test on the blocking effect of the mixture of casein blocking component and animal hemoglobin blocking component on casein and animal hemoglobin (reagent used is Feipeng Bio human hemoglobin antibody)
[0068] In order to test whether the mixture of casein blocking components and animal hemoglobin blocking components itself would interfere with the determination of human hemoglobin, 1-4% blocking components (casein antibody: pig hemoglobin antibody: bovine hemoglobin antibody = 1:1:1) were added to the R1 reagent to test gradient concentrations of human hemoglobin standards. The results are shown in Table 5.
[0069] Table 5
[0070]
[0071] In order to test the blocking effect of the mixture of casein blocking components and animal hemoglobin blocking components, 1-4% blocking components (casein antibody: pig hemoglobin antibody: bovine hemoglobin antibody = 1:1:1) were added to the R1 reagent respectively, and gradient concentrations of casein standards and animal hemoglobin standards were tested. The results are shown in Tables 6 and 7.
[0072] Table 6
[0073]
[0074] Table 7
[0075]
[0076] From the above results, it can be seen that after adding blocking components to the reagent in R1, the interference caused by casein and animal hemoglobin can be significantly eliminated, and the added concentration of the blocking components with food-borne proteins shows a dose-dependent effect. At the same time, when the added concentration is between 0.1% and 2%, it does not affect the activity of the reagent. Continuing to increase the added concentration will cause the detection activity of the reagent to decrease slightly. The preferred concentration of the blocking components is 0.5%-2%.
[0077] Test Example 4: Test on the effect of a mixture of casein blocking components and animal hemoglobin blocking components on human hemoglobin determination, and test on the blocking effect of a mixture of casein blocking components and animal hemoglobin blocking components on casein and animal hemoglobin (Dako human hemoglobin antibody used as reagent)
[0078] The operation process is the same as that of Test Example 3, except that the human hemoglobin antibody in the detection reagent is Dako A0118. The results are shown in Tables 8, 9 and 10.
[0079] Table 8
[0080]
[0081] Table 9
[0082]
[0083]
[0084] Table 10
[0085]
[0086] From the above results, it can be seen that the addition of protein blocking components in R1 can significantly eliminate the interference caused by casein and animal hemoglobin, and the effect is dose-dependent with the concentration of blocking components added. However, the addition of blocking components will also affect the activity of the reagent. In summary, the preferred concentration of blocking components added is 0.5%-1%.
[0087] It can be seen that the antibody-coupled latex reagents prepared with human hemoglobin antibodies produced by different manufacturers will be interfered by casein, but the degree of influence is different, and the amount of blocking components needs to be adjusted accordingly.
[0088] Test Example 5 Elimination Effect of Casein Blocking Components and Mixtures of Casein Blocking Components and Animal Hemoglobin Blocking Components on Clinical False Positive Samples
[0089] If casein in stool samples is not removed in advance and blocking components are not used during the test, the use of latex-enhanced immunoturbidimetric reagent to detect fecal human hemoglobin will result in about 4% false positive results. Casein blocking components (casein antibodies), casein blocking components and animal hemoglobin blocking components (casein antibodies: pig hemoglobin antibodies: bovine hemoglobin antibodies = 1:1:1) were added to the R1 reagent, and then these few false positive samples (the instrument detection reading is judged to be positive if it exceeds 100, and the detection value of clinical samples by Rongyan Yiyou's detection reagents and the matching stool analyzer is assumed to be the standard value) were tested, and the results are shown in Table 11 below.
[0090] Table 11
[0091]
[0092]
[0093] It can be seen that for the original 8 clinical false-positive samples, adding casein blocking components to the detection reagent can eliminate the false-positive results of 4 of the clinical samples, which proves that a large proportion of the false-positive test results of patients with fecal occult blood are caused by residual casein in the feces. Further adding animal hemoglobin blocking components to the detection reagent can further eliminate the false-positive results of 2 clinical samples, which shows that adding casein blocking components and animal hemoglobin blocking components at the same time can eliminate the false-positive test results of clinical samples to the greatest extent.
[0094] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0095] The above-described embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solutions of the present invention in detail, but cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description can be used to interpret the contents of the claims.
Claims
1. An immunoassay reagent for a target analyte in a stool sample, characterized in that: It comprises a casein blocking component; the target analyte is human hemoglobin, the immunoassay is an immunoturbidimetric assay, and the casein blocking component is selected from at least one of an antibody and an antiserum against casein.
2. The immunoassay reagent for detecting the target analyte in a stool sample according to claim 1, wherein: The immunoassay reagent is at least one of a sample diluent, a sample processing solution, an immunoturbidimetric R1 reagent, and an immunoturbidimetric R2 reagent.
3. The immunoassay reagent for detecting a target analyte in a stool sample according to claim 1, wherein: An animal hemoglobin blocking component is also included.
4. The immunoassay reagent for detecting a target analyte in a stool sample according to claim 3, wherein: The animal hemoglobin blocking component is selected from at least one of an antibody and an antiserum against animal hemoglobin.
5. The immunoassay reagent for detecting the target analyte in a stool sample according to claim 4, characterized in that: The animal hemoglobin is selected from at least one of porcine hemoglobin, bovine hemoglobin, sheep hemoglobin, chicken hemoglobin, duck hemoglobin and fish hemoglobin.
6. A kit, characterized in that: The immunoassay reagent comprises the immunoassay reagent according to any one of claims 1 to 5.
7. Use of a casein blocking component in preparing an immunoassay reagent for a target analyte in a stool sample, wherein the target analyte is human hemoglobin, the immunoassay is an immunoturbidimetric assay, and the casein blocking component is selected from at least one of an antibody and an antiserum against casein.
8. The use according to claim 7, wherein the immunoassay reagent is at least one of a sample diluent, a sample processing solution, a sample diluent, an immunoturbidimetric R1 reagent, and an immunoturbidimetric R2 reagent.
9. A method for eliminating false positive results of an immunoassay of a target analyte in a stool sample, characterized in that: The stool sample is pretreated with a casein blocking component to remove casein; the casein blocking component is selected from at least one of an antibody and an antiserum against casein; the target analyte is human hemoglobin, and the immunoassay is an immunoturbidimetric assay.
